Modified Nucleosides
1-[(5E)-5,6-Dideoxy-6-phosphono-2-O-methyl-β-D-ribo-hex-5-enofuranosyl)uracil
Quick view. We supply 1-[(5E)-5,6-Dideoxy-6-phosphono-2-O-methyl-β-D-ribo-hex-5-enofuranosyl)uracil as a specialty product for nucleic acid chemistry and oligonucleotide research workflows. CAS 2095417-50-6. Catalog target purity: Specification on request.
Structure and identity
The structure drawing for this item is being finalized. Use the CAS number and machine-readable identifiers below to confirm the requested protecting groups, stereochemistry, salt or counterion and hydration state before ordering.
CAS, molecular formula, SMILES or InChI data are shown below when available.
We withhold a drawing when a related compound, alternate salt or incompletely specified stereoisomer could be mistaken for the requested material.
Agreed identity and purity criteria are documented in the quotation, specification and lot-specific data package.
Product profile
1-[(5E)-5,6-Dideoxy-6-phosphono-2-O-methyl-β-D-ribo-hex-5-enofuranosyl)uracil is classified as nucleoside or protected nucleoside intermediate (Formula C11H15N2O8P; molecular weight 334.22).
1-[(5E)-5,6-Dideoxy-6-phosphono-2-O-methyl-β-D-ribo-hex-5-enofuranosyl)uracil can serve as a starting material, protected intermediate or analytical comparator in nucleoside and nucleotide route development.
For 1-[(5E)-5,6-Dideoxy-6-phosphono-2-O-methyl-β-D-ribo-hex-5-enofuranosyl)uracil, polymerase acceptance varies; absence of a 3′-OH prevents further extension after incorporation.
Names and search terms
Useful catalog search terms
- CAS 2095417-50-6
- Nucleoside or protected nucleoside intermediate
- Modified Nucleosides
Release documentation
The current specification defines the analytical method and acceptance criteria; the released lot result is reported on the CoA.
Additional HPLC, MS or NMR documentation can be agreed during technical review where available.
Additional application examples
- Typical work includes protection/deprotection studies, phosphorylation or phosphitylation route scouting and impurity identification.
- The material can support medicinal-chemistry analog preparation and process-development feasibility studies.
Product-specific evaluation notes
Potential advantages
- Dideoxy analogs provide clear extension-stop behavior when accepted by a polymerase.
Method limitations
- Polymerase acceptance varies; absence of a 3′-OH prevents further extension after incorporation.
These points describe 1-[(5E)-5,6-Dideoxy-6-phosphono-2-O-methyl-β-D-ribo-hex-5-enofuranosyl)uracil or its named chemical feature. Broader product-family guidance is maintained on the category page.
Related products
(S)-cEt-rA
Modified Nucleosides · CAS: 1197033-34-3
BX-OP-0069S-Adenosylmethionine (SAM)
Modified Nucleosides · CAS: 485-80-3
BX-MN-0185(R-/S-) 5-Carbamoylhydroxy methyluridine
Modified Nucleosides · CAS: N/A
BX-MN-0186(R-/S-)5-(1-Hydroxy)(methoxycarbonyl)methyl uridine
Modified Nucleosides · CAS: N/A
BX-MN-0187(R-/S-)5-Carboxyhydroxymethyl uridine
Modified Nucleosides · CAS: N/A
BX-MN-0719(R)-N-(2,3-dihydro-1H-indenyl)adenosine
Modified Nucleosides · CAS: 96392-15-3
Frequently asked questions
Can the package size for 1-[(5E)-5,6-Dideoxy-6-phosphono-2-O-methyl-β-D-ribo-hex-5-enofuranosyl)uracil be customized?
Yes. Share the initial quantity, expected future scale, delivery timeline and packaging preference for review.
What information should be included in a quote request?
Quote catalog number BX-MN-0817 and CAS 2095417-50-6, the intended research workflow, required quantity and any additional HPLC, MS or NMR documentation needed.
Product-family literature
The publications below provide peer-reviewed context for the Modified Nucleosides product family and its named chemistry.